493 related articles for article (PubMed ID: 27279064)
1. The effect of excipients on the stability and aerosol performance of salmon calcitonin dry powder inhalers prepared via the spray freeze drying process.
Poursina N; Vatanara A; Rouini MR; Gilani K; Najafabadi AR
Acta Pharm; 2016 Jun; 66(2):207-18. PubMed ID: 27279064
[TBL] [Abstract][Full Text] [Related]
2. Novel Budesonide Particles for Dry Powder Inhalation Prepared Using a Microfluidic Reactor Coupled With Ultrasonic Spray Freeze Drying.
Saboti D; Maver U; Chan HK; Planinšek O
J Pharm Sci; 2017 Jul; 106(7):1881-1888. PubMed ID: 28285981
[TBL] [Abstract][Full Text] [Related]
3. Development of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach.
Karimi K; Pallagi E; Szabó-Révész P; Csóka I; Ambrus R
Drug Des Devel Ther; 2016; 10():3331-3343. PubMed ID: 27784991
[TBL] [Abstract][Full Text] [Related]
4. The effects of excipients and particle engineering on the biophysical stability and aerosol performance of parathyroid hormone (1-34) prepared as a dry powder for inhalation.
Shoyele SA; Sivadas N; Cryan SA
AAPS PharmSciTech; 2011 Mar; 12(1):304-11. PubMed ID: 21271316
[TBL] [Abstract][Full Text] [Related]
5. Application of cyclodextrins in antibody microparticles: potentials for antibody protection in spray drying.
Ramezani V; Vatanara A; Seyedabadi M; Nabi Meibodi M; Fanaei H
Drug Dev Ind Pharm; 2017 Jul; 43(7):1103-1111. PubMed ID: 28276783
[TBL] [Abstract][Full Text] [Related]
6. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
Li X; Vogt FG; Hayes D; Mansour HM
Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
[TBL] [Abstract][Full Text] [Related]
7. Co-spray dried carbohydrate microparticles: crystallisation delay/inhibition and improved aerosolization characteristics through the incorporation of hydroxypropyl-β-cyclodextrin with amorphous raffinose or trehalose.
Amaro MI; Tajber L; Corrigan OI; Healy AM
Pharm Res; 2015 Jan; 32(1):180-95. PubMed ID: 25074469
[TBL] [Abstract][Full Text] [Related]
8. Design, characterization, and aerosol dispersion performance modeling of advanced spray-dried microparticulate/nanoparticulate mannitol powders for targeted pulmonary delivery as dry powder inhalers.
Li X; Vogt FG; Hayes D; Mansour HM
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):81-93. PubMed ID: 24502451
[TBL] [Abstract][Full Text] [Related]
9. Influence of Formulation Factors on the Aerosol Performance and Stability of Lysozyme Powders: a Systematic Approach.
Ferrati S; Wu T; Fuentes O; Brunaugh AD; Kanapuram SR; Smyth HDC
AAPS PharmSciTech; 2018 Oct; 19(7):2755-2766. PubMed ID: 29488193
[TBL] [Abstract][Full Text] [Related]
10. Formulation, stability and pharmacokinetics of sugar-based salmon calcitonin-loaded nanoporous/nanoparticulate microparticles (NPMPs) for inhalation.
Amaro MI; Tewes F; Gobbo O; Tajber L; Corrigan OI; Ehrhardt C; Healy AM
Int J Pharm; 2015 Apr; 483(1-2):6-18. PubMed ID: 25660067
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of salmon calcitonin in spray-dried powder for inhalation. Effect of chitosan.
Yang M; Velaga S; Yamamoto H; Takeuchi H; Kawashima Y; Hovgaard L; van de Weert M; Frokjaer S
Int J Pharm; 2007 Mar; 331(2):176-81. PubMed ID: 17126507
[TBL] [Abstract][Full Text] [Related]
12. Dry-powder formulations of non-covalent protein complexes with linear or miktoarm copolymers for pulmonary delivery.
Nieto-Orellana A; Coghlan D; Rothery M; Falcone FH; Bosquillon C; Childerhouse N; Mantovani G; Stolnik S
Int J Pharm; 2018 Apr; 540(1-2):78-88. PubMed ID: 29425761
[TBL] [Abstract][Full Text] [Related]
13. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.
Park CW; Li X; Vogt FG; Hayes D; Zwischenberger JB; Park ES; Mansour HM
Int J Pharm; 2013 Oct; 455(1-2):374-92. PubMed ID: 23820131
[TBL] [Abstract][Full Text] [Related]
14. Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation.
Fabio K; Curley K; Guarneri J; Adamo B; Laurenzi B; Grant M; Offord R; Kraft K; Leone-Bay A
AAPS PharmSciTech; 2015 Dec; 16(6):1299-306. PubMed ID: 25776985
[TBL] [Abstract][Full Text] [Related]
15. Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients.
Minne A; Boireau H; Horta MJ; Vanbever R
Eur J Pharm Biopharm; 2008 Nov; 70(3):839-44. PubMed ID: 18620052
[TBL] [Abstract][Full Text] [Related]
16. Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells.
Aquino RP; Prota L; Auriemma G; Santoro A; Mencherini T; Colombo G; Russo P
Int J Pharm; 2012 Apr; 426(1-2):100-107. PubMed ID: 22301426
[TBL] [Abstract][Full Text] [Related]
17. Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride.
Karimi K; Katona G; Csóka I; Ambrus R
J Pharm Biomed Anal; 2018 Jan; 148():73-79. PubMed ID: 28965047
[TBL] [Abstract][Full Text] [Related]
18. Particle engineering of materials for oral inhalation by dry powder inhalers. I-Particles of sugar excipients (trehalose and raffinose) for protein delivery.
Ogáin ON; Li J; Tajber L; Corrigan OI; Healy AM
Int J Pharm; 2011 Feb; 405(1-2):23-35. PubMed ID: 21129458
[TBL] [Abstract][Full Text] [Related]
19. Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin.
Shetty N; Ahn P; Park H; Bhujbal S; Zemlyanov D; Cavallaro A; Mangal S; Li J; Zhou QT
Mol Pharm; 2018 Sep; 15(9):4004-4020. PubMed ID: 30028947
[TBL] [Abstract][Full Text] [Related]
20. Dry powders for inhalation containing monoclonal antibodies made by thin-film freeze-drying.
Hufnagel S; Xu H; Sahakijpijarn S; Moon C; Chow LQM; Williams Iii RO; Cui Z
Int J Pharm; 2022 Apr; 618():121637. PubMed ID: 35259440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
